RANCHO CORDOVA, Calif., Sept. 4, 2012 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing, storage and administration of cell therapies, announced today a new integrated distribution agreement in Europe with Concessus for its cord blood products—the AXP ® AutoXpress ® (AXP) System and BioArchive ® System.
The AXP System is a proprietary family of automated devices with companion sterile blood processing disposables for harvesting cord blood stem cells in closed systems and the BioArchive System is an automated robotic device for cryopreserving and archiving cord blood stem cell units for transplant.
Under the four-year agreement, Concessus will distribute both the AXP and BioArchive in the following countries: France, Spain, Switzerland, Benelux, Liechtenstein and Nordic countries (excluding Iceland). Concessus, which has been distributing the BioArchive since 2010, is a nearly 50-year-old Lisbon-based company that has been involved in the cord blood market for more than two decades. Concessus specializes in equipment for the healthcare diagnostic laboratory and research markets, with a strong focus on key markets in Western Europe.GE Healthcare, which had been distributing the AXP in these markets, will continue to distribute the offering in the U.S. and Canada. "This is an important development in our market expansion strategy as it represents a customer-centric approach that incorporates marketing, service and support for both of our cord blood products with one channel partner. We believe this agreement, in concert with our leading-edge technology, will not only strengthen our relationships with existing customers, but also enhance our competitive position in these important geographies," said Hal Baker, Head of Commercial Operations for ThermoGenesis. "Representing the AXP now together with the BioArchive in Western Europe creates a meaningful competitive advantage for us in the cord blood market," said João Araújo, Chief Executive Officer of Concessus. "We are now the only organization in Western Europe offering fully automated cell processing and cell storage products and services for the cord blood market," he continued.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV